<DOC>
	<DOCNO>NCT02877459</DOCNO>
	<brief_summary>A multicenter , prospective , single-arm clinical investigation evaluate short term long term safety modify staged treatment algorithm use AeriSeal System .</brief_summary>
	<brief_title>Clinical Investigation Modified Staged Treatment Algorithm Using AeriSeal System</brief_title>
	<detailed_description>The AeriSeal-STAGE trial prospective , multicenter study intend evaluate safety modify staged treatment algorithm escalation dose use AeriSeal System treatment subject severe emphysema control trial design set compare publish data prior study . The trial anticipate enroll fifteen ( 15 ) study subject homogeneous , upper lobe predominant heterogeneous emphysema , three ( 3 ) center Europe .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<criteria>1 . Subject willing able provide inform consent participate study 2 . Subject ≥ 40 year age 3 . Subject diagnosis homogenous heterogeneous upper lobe predominant emphysema confirm computerized tomography ( CT ) scan . 4 . Subject least two ( 2 ) nonadjacent subsegments appropriate treatment base upon CT scan 2 different upper lobe segment lung ( total 4 available subsegments ) 5 . Subject clinically significant dyspnea score &gt; 1 mMRC scale 0 4 6 . Subject SixMinute Walk Test ( 6MWT ) distance ≥ 250 meter 7 . Subject postbronchodilator FEV1 ≤ 45 % predict 8 . Subject Total Lung Capacity &gt; 100 % predict 9 . Subject Residual Volume &gt; 175 % predict 10 . Subject stop smoke least 8 week prior enter study confirm carboxyhemoglobin cotinine level 11 . Subject receive preventive vaccination potential respiratory infection consistent local recommendation policy 1 . Subject severe bullous emphysema judge Investigator . 2 . Subject prior lung volume reduction surgery , prior lobectomy pneumonectomy , prior lung transplantation , prior airway stent placement , prior pleurodesis , prior endobronchial lung volume reduction therapy type 3 . Subject evidence active respiratory infection 4 . Subject ongoing chronic obstructive pulmonary disease ( COPD ) exacerbation bronchospasm 5 . Subject know allergy device component : 1 . Polyether block amide PEBAX® 2 . Polyvinyl Alcohol 3 . Glutaraldehyde 6 . Subject require ventilatory support ( invasive noninvasive ) 7 . Subject diffuse capacity lung carbon monoxide ( DLco ) &lt; 20 % predict 8 . Subject postbronchodilator FEV1 &lt; 20 % predict 9 . Subject tolerate corticosteroid relevant antibiotic 10 . Subject relevant comorbidities judge Investigator , deconditioned tolerate stress posttreatment inflammatory response 11 . Subject history recurrent clinically significant respiratory infection , define three ( 3 ) COPD exacerbation require hospitalization year prior enrollment 12 . Subject severe gas exchange abnormality define one following : 1 . Partial pressure arterial carbon dioxide ( PaCO2 ) &gt; 55 mm Hg 2 . Partial pressure arterial oxygen ( PaO2 ) &lt; 45 mm Hg room air 3 . Peripheral capillary oxygen saturation ( SpO2 ) &lt; 90 % ≥ 4 L/min supplemental O2 , rest 13 . Subject Pulmonary hypertension , define peak systolic pressure &gt; 45 mm Hg echocardiogram right heart catheterization 14 . Subject use systemic steroid &gt; 20 mg/day equivalent and/or immunosuppressive agent 4 week prior procedure 15 . Subject unable temporarily interrupt use heparins oral anticoagulant ( e.g. , warfarin , dicumarol ) per Institutional recommendation . Note : antiplatelet drug include aspirin clopidogrel permit 16 . Subject alpha1 antitrypsin serum level &lt; 80 mg/kg ( i.e . &lt; 11 µmol/L ) Screening 17 . Subject 's CT scan indicate presence follow radiologic abnormality : 1 . Pulmonary nodule CT scan great 0.8 cm diameter [ Does apply present 2 year without increase size proven benign biopsy/positron emission tomography ( PET ) ] 2 . Radiologic picture consistent active pulmonary infection , e.g. , unexplained parenchymal infiltrate 3 . Significant interstitial lung disease 4 . Significant pleural disease 18 . Subject 's baseline electrocardiogram ( EKG ) indicate arrhythmias conduction abnormality 19 . Subject high cardiac risk undergo cardiac risk assessment accordance publish guideline ischemic heart disease , congestive heart failure , renal failure cerebrovascular disease 20 . Clinically significant asthma ( reversible airway obstruction ) , chronic bronchitis , bronchiectasis 21 . Allergy sensitivity medication require safely perform bronchoscopy AeriSeal System treatment general anesthesia conscious sedation 22 . Participation investigational study drug , biologic , device within 30 day prior enter study plan course study . 23 . Body mass index ( BMI ) &lt; 15 kg/m2 &gt; 35 kg/m2 24 . Female subject pregnant breastfeeding 25 . Abnormal screen laboratory test result compare reference lab normal individual site follow : 1 . Blood urea nitrogen &gt; 1.5 x upper limit normal 2 . Creatinine &gt; 1.5 x upper limit normal 3 . Aspartate aminotransferase &gt; 1.5 x upper limit normal 4 . Alanine aminotransferase &gt; 1.5 x upper limit normal 5 . Alkaline phosphatase &gt; 1.5 x upper limit normal 6 . White blood cell ( total ) absolute &lt; 3 x 109/L &gt; 1.25 x upper limit normal 7 . Hematocrit &lt; 34 &gt; 1.25 x upper limit normal 8 . Platelets &lt; 100 &gt; 450 K/µL 9 . Prothrombin time International Normalized Ratio ( INR ) &gt; 1.5 x upper limit normal 10 . Partial thromboplastin time &gt; 1.5x upper limit normal 11 . Positive Beta human chorionic gonadotropin ( βHCG ) Pregnancy test ( female ) 26 . Subject evidence severe disease judgment investigator may compromise survival duration study ( 24 month ) e.g . : 1 . Human immunodeficiency virus ( HIV ) /acquired immune deficiency syndrome ( AIDS ) 2 . Active malignancy 3 . Stroke Transient ischemic attack ( TIA ) within 12 month Screening visit 4 . Myocardial infarction within 6 month Screening visit 5 . Congestive heart failure within 6 month Screening visit define clinical evidence right leave heart failure leave ventricular ejection fraction &lt; 45 % echocardiogram 27 . Subject diagnosed diabetes mellitus 28 . Any condition Investigator believe would interfere intent study would make participation best interest subject i.e. , alcoholism , high risk drug abuse noncompliance return followup visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>